NEWS

WIRES

OTHER

OmniComm Systems, Inc. Enters Into an Enterprise Electronic Data Capture (EDC) Agreement Worth $8-10 Million With a Major Biotechnology Company

Company Continues to Expand Its Footprint by Providing Leading-Edge, Integrated EDC Solutions and Services to Its Rapidly Growing Customer Base

OmniComm Systems, Inc. (OTCBB: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced that the company has entered into a 5-year, multi-million dollar enterprise agreement with a major west coast biotechnology company. The agreement allows the biotech company to take full advantage of OmniComm's First in Functionality(TM), EDC solution, TrialMaster(TM) for up to 10 concurrent trials per year. The biotech company will strategically utilize OmniComm's EDC application to assist in managing their global clinical trials and clinical related data. The enterprise deal includes complete licensing, services and technical support for these 10 concurrent studies. The agreement also provides for an option to exceed 10 concurrent studies per year for a predetermined 'per study' price.

"Of course we are very excited to be chosen by such a prestigious company to manage their clinical trials over the next 5 years," said Stephen Johnson, Chief Operating Officer of OmniComm. "Their commitment to us is matched only by our commitment to our customers to deliver best of breed solutions that integrate seamlessly into their clinical environment. And we back this up with industry leading customer service & support teams."

OmniComm is committed to providing their customers with comprehensive, world-class customer service and support. A key component of OmniComm's service offering is a dedicated Clinical Services division that provides its customers with extensive clinical trial industry experience. This team of industry professionals oversees the database creation and data dictionary design process and offers a variety of consulting services including protocol design, process revision and FDA submission services as part of the study build process. OmniComm also offers a comprehensive learning environment that includes Instructor led, live or web-based training, eLearning, train-the-trainer or a customized approach that is designed for the clients' specific needs.

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Germany, Tula, Russia, California, Maryland, New York, North Carolina and Texas.

Safe Harbor Disclaimer

Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.